Provided by Tiger Trade Technology Pte. Ltd.

Sierra Oncology Inc

54.99
0.0000
Volume:- -
Turnover:47.45M
Market Cap:1.34B
PE:-8.34
High:54.99
Open:54.99
Low:54.99
Close:54.99
52wk High:55.19
52wk Low:14.91
Shares:24.42M
Float Shares:13.42M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5912
EPS(LYR):-7.1427
ROE:-56.54%
ROA:-32.85%
PB:5.13
PE(LYR):-7.70

Loading ...

Company Profile

Company Name:
Sierra Oncology Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.